COVID-19 therapeutic drugs including Remdesivir have 'little or no' benefit, says WHO

results of UN-coordinated trial of four anti-viral drugs for treatment of COVID-19 have indicated that y have “little or ” positive impact in reducing mortality rate of patients, said World Health Organisation (WHO) in a statement on October 16. What United Nations (UN) health ncy called “world’s largest randomized control trial” on COVID-19 rapeutics which lasted for six months, has generated conclusive evidence on effectiveness of repurposed medications - Remdesivir, hydroxychloroquine, lopinavir/ritonavir and interferon for treating COVID-19 patients. 

However, WHO concluded that se four COVID-19 rapeutics “appeared to have little or effect on 28-day mortality or in-hospital course of COVID-19 among hospitalized patients.”

Spanning in over 30 countries, ‘Solidarity rapeutics Trial’ overseen by WHO h begun in March to monitor effects of se treatments on overall mortality, need for ventilation, along with duration for which patient is required to hospitalised. Meanwhile, or uses of four mentioned repurposed drugs such as treatment of COVID-19 patients in community or for preventing spre of infections, would be included in separate trials.

results of trial are currently under review for publication in a medical journal but have been uploed as a preprint at medRxiv. It concluded by saying, “ study drug definitely reduced mortality (in unventilated patients or any or subgroup of entry characteristics), initiation of ventilation or hospitalisation duration.”

Re - China's Drug Company Says Its Treatment Could Potentially 'inhibit' Covid-19

Re - Covid Cure? Trump Wants Experimental Drug Regeneron He Used Cleared By FDA; 'bugging m'

Blood-pressure risks associated with COVID-19

Meanwhile, in a separate but related anuncement, WHO said that COVID-19 has also highlighted increased vulnerability of people with high blood pressure to COVID-19. Based on data from more than 120 countries that showed significant COVID-19-related disruption to treatment of people suffering from chronic health conditions, UN health ncy warned that such patients make up 50 to 60 per cent of all deaths from vel coronavirus infections. 

As per UN statement, Dr Bente Mikkelsen, Director of WHO’s Department of ncommunicable Diseases has ted that more than 1.13 billion people around world suffer from hypertension. Moreover, of this number, 745,800,000 reside in low and middle-income nations and 80 per cent of se countries have less than 50 per cent of people on treatment.  

Re - 'Submit Covaxin's Phase II Data Before Proceeding For Phase III': CDSCO To Bharat Biotech

Re - European Commission To Procure Remdesivir Drug Amid Short; Pens New Deal With Gile

Im: AP